Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
November 4, 2021
Earnings Call Speaker Segments
Brian Blanchett
executiveGood afternoon to all of you, and thank you for joining us on this call covering the third quarter of 2021. On today's call, we're going to walk through the financial results that were issued following the market close, and we'll also share some commentary regarding our commercial activity, and following that, we'll hold a question answer session. Should you not have had an opportunity to look over the earnings release, you can locate it in the investor relations portion of our website at illumina.com. Here for Illumina today are Francis deSouza, President and Chief Executive Officer, along with Sam Samad, Chief Financial Officer; Bob Ragusa, Chief Executive Officer of GRAIL, is also with us today. Francis is going to give an update regarding the state of Illumina's business. Bob is going to share updates regarding GRAIL's business, and Sam is going to walk through financial results for both Core Illumina and GRAIL; this call is being recorded, and the audio portion is going to be archived in the investor section of our website. Our intention is that all forward-looking statements about our financial results and the commercial activity made on today's call are going to be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. Actual events or results might differ materially from those projected or discussed. All forward-looking statements rest upon information currently available, and Illumina takes on no obligation to update these statements. To better grasp the risks and uncertainties that might cause actual results to differ, please refer to the documents Illumina files with the Securities and Exchange Commission, including Illumina's most recent forms 10-Q and 10-K. With that, I'll now hand the call over to Francis.
Francis deSouza
executiveThanks, Brian, and good afternoon to all of you. For Illumina, the third quarter proved to be yet another remarkably robust period, delivering $1.108 billion in revenue — a 40% increase compared with the same quarter a year earlier — and once again, it came in well above what had been anticipated. Our customer base keeps growing at a fast clip, and during the first three quarters of 2021, the number of new customers we brought in was 50% greater than what we added across the entirety of 2020 or 2019. Given that level of strength throughout our business, for the third consecutive quarter we are lifting our outlook for full-year revenue growth, now to roughly 36%. That figure represents about twice the growth rate and $567 million more than the midpoint of the range we provided as guidance at the start of the year. I'll walk through the third quarter results for core Illumina, which we define as Illumina excluding Grail, and after that I'll hand things over to Bob Ragusa, who serves as CEO of our Grail subsidiary, so he can discuss the Grail business. Core Illumina revenue came in at $1.106 billion. Revenue from sequencing instruments rose 65% versus the prior-year quarter, and we finished the quarter with a record backlog for instruments, which is a favorable leading indicator for revenue going forward. Sequencing activity during the quarter was robust as well, with sequencing consumable revenue climbing 45% compared with a year earlier and reaching a new record. Order volume for our high-throughput platform is picking up speed. Oncology testing, population sequencing, and drug discovery initiatives fueled record shipments of NovaSeq consumables and instruments. For the quarter, oncology testing customers made up the largest share of NovaSeq shipments, as sizable oncology testing labs expanded their fleets to support broader reimbursement for therapy selection testing. Drug discovery is emerging as a new application for high-throughput sequencing, with opportunities spanning common diseases from obesity to aging. Growth was also driven by our mid-throughput platforms, which enlarged our install base. During the third quarter, more than 50% of NextSeq 1000 and 2000 placements went to customers who were new to Illumina or who were upgrading from low-throughput instruments. These instruments keep opening up new applications. At Tulane School of Medicine, researchers are employing the NextSeq 2000 for single-cell experiments centered on infection and inflammation. In a recent paper published in Science Immunology, the team is working to create inhaled vaccines for pneumonia and is using single-cell RNA-Seq on a NextSeq 2000 to examine the immune cells triggered by this vaccine platform. Benchtop platforms likewise experienced substantial growth versus a year earlier, recording the largest number of MiSeq shipments since Q4 2015. When paired with our COVIDSeq 96-sample assay, MiSeq is allowing labs worldwide to take part in local pathogen surveillance. In both Argentina and Brazil this quarter, MiSeq placements extended COVID surveillance to local communities alongside broader national programs; now, moving to the clinical, research, and applied segments, oncology testing, our biggest market segment, delivered another record quarter. Sequencing is turning into the standard of care for therapy selection, which is generating strong demand for Illumina sequencers, and our oncology testing customers are scaling up their fleets quickly in response. Reimbursement for genetic testing for therapy selection keeps widening, with more than 70% of insured lives in the U.S. now covered for these tests. On top of that, more than 60 therapies aimed at specific targets or harnessing the immune system are available for patients right now, which shows how much comprehensive genomic profiling can do when it comes to pairing people with the right treatment. Our research use only comprehensive genomic profiling assay, TruSight Oncology 500, posted yet another record quarter, and the number of customers running it in their own labs has climbed past 340. Back in September, we told you about a CDX collaboration with Merck through which we will develop and commercialize tests that draw on TSO 500 content along with an HRD status built on Myriad's myChoice for ovarian cancer patients. Each year, roughly 300,000 women globally receive an ovarian cancer diagnosis, and it ranks as the fifth deadliest cancer among women. Through this partnership, those patients should gain access to more treatment choices, with better care as the aim. Over in reproductive health, we delivered another quarter of robust growth compared with a year earlier. Non-invasive prenatal testing is now covered for close to 80% of pregnancies in the U.S., and things keep moving forward as states start folding the ACOG guideline revision from last year into their prenatal screening programs. California is reworking its prenatal screening program so that non-invasive prenatal testing is included, and the state has issued a request for proposal. Beyond the U.S., NIPT keeps finding its way into guidelines too. In September, the Italian Ministry of Health released new guidelines endorsing NIPT within a contingent model; given this ongoing momentum on coverage and guidelines, our end-to-end VeriSeq v2 solution is picking up traction in markets worldwide. Genetic disease testing likewise had another solid quarter, since widespread reimbursement and persuasive clinical utility data are pushing a shift toward whole-genome sequencing. During this quarter, results from the landmark NICUSeq trial, which Illumina scientists co-authored, appeared in JAMA Pediatrics. That randomized controlled trial showed clinical whole-genome sequencing produces a twofold gain in diagnostic efficacy as well as in change of clinical management for newborns who are acutely ill. We are striving to make sure families and NICU patients everywhere can get these tests; here in the U.S., Michigan just became the first state to provide rapid whole-genome sequencing to acutely ill infants and children, with no regard for insurance status. California and Florida are among other states moving forward on this front too. Abroad, last week we unveiled a pilot program in Israel to bring whole-genome sequencing to critically ill infants in neonatal intensive care units who are suspected of having a genetic disorder. That program will shorten the path to diagnosis for these patients and assist with swift clinical decision-making. Now to our research and applied segments, where we once again enjoyed a strong quarter of sequential and year-over-year growth. The 30+ population genomics initiatives we back across the globe fueled growth during the quarter. With the accuracy and scalability of our sequencing platforms, paired with end-to-end solutions such as Illumina Connected Analytics, Illumina is the perfect partner for large sequencing initiatives. The worth of these population initiatives keeps growing in areas like clinical outcomes, research, and drug discovery; that momentum is drawing considerable attention and funding toward further programs such as Our Future Health, which stands as the U.K.'s biggest research effort ever, aimed at creating new methods to detect, treat, and prevent disease. Only yesterday, we shared that Illumina Connected Analytics solutions are being utilized by HostSeq, which is part of the Canadian COVID-19 Genomics Network. Our sequencing and bioinformatic tools are going to be applied toward pinpointing biomarkers able to assist in predicting possible risk of severe illness and to back the creation of innovative therapeutics for fighting COVID-19. We expect these kinds of population programs will grow ever more essential to innovation, since what they uncover leads to wider adoption of sequencing within clinical workflows and usable data for drug discovery. That's already apparent with the early data coming from the UK Biobank as those programs wrap up. Regeneron is putting UK Biobank data to work in several ways, among them locating over 500 genes with variant trait associations tied to elevated disease risk such as hypertension, asthma, and liver disease, plus using it within their data set to develop new obesity medicines alongside AstraZeneca. Firms such as Relay Therapeutics are applying genomic data together with AI and machine learning to push drug discovery forward. COVID surveillance accounted for $55 million in sequencing shipments during the quarter, $15 million of which came from instrument purchases, as worries over variants keep sharpening attention on surveillance work; we view the infrastructure built for COVID surveillance as a base for wider pathogen surveillance that will expand globally. To illustrate, CERI, a fresh genomics facility located in South Africa, opened this quarter, equipped to strengthen pandemic and epidemic response throughout Africa; with such resources now available, sequencing data from 51 of Africa's 54 countries can currently be found in GISAID, and 50,000 SARS-CoV-2 genomes in total have been sequenced, coming two months prior to Africa CDC's timeline. Shifting to GRAIL, we completed our acquisition in August, which we think will assist in speeding up patient access and affordability for multi-cancer early detection screening. I'm pleased to welcome Bob Ragusa on his debut call as GRAIL's CEO. Bob previously held the role of Illumina's Chief Operations Officer, and he brings over 30 years of genomics experience. He was instrumental in supplying the sequencing systems used for the Human Genome Project, and he oversaw major expansion of Illumina's business across more than 140 countries and made the first NovaSeq shipments possible. Given his decades of profound knowledge, Bob is ideally suited to steer GRAIL through this period of remarkable growth and discovery. I'll now hand the call over to Bob so he can go over GRAIL's business updates.
Bob Ragusa
executiveFrancis deSouza, thank you. It's a privilege to guide the skilled group here at GRAIL as we move the mission forward — finding cancer early, at a point when it can still be cured. I'd like to offer a few reflections on where we stand right now. To start, let me call attention to how Galleri is performing commercially. Before reimbursement arrives, we see substantial opportunities for Galleri, and the energy across our three main channels gives us encouragement. Within the employer channel, momentum is building, and we anticipate announcing major new partnerships in technology, industrial, professional services, and transportation. We're also making solid headway with public sector employers located in high cancer risk areas, firefighters among them. When it comes to health systems, our attention is on forging strategic agreements with leading systems in the medical community, which will build both awareness of and hands-on experience with Galleri. These systems also serve as strategic collaborators for producing real-world evidence within key patient communities and regions. As of today, we've signed agreements with multiple health partners who intend to begin offering access to Galleri during the fourth quarter. Beyond that, contract talks are underway with a number of other influential health systems, and we anticipate they will start making Galleri available to patients in early 2025. We're also thrilled by the interest coming from forward-thinking, innovative payers, Medicare Advantage included, and we look to share news of our first partnership before long. Medical practices play a major role in driving the Galleri launch. We've reached agreements with a number of the biggest primary care private practice networks and anticipate further expansion here. Our efforts center on onboarding physicians within those networks, and prescriber trends look favorable. We also recently teamed up with Genome Medical, an independent healthcare provider, to reach people who would rather use a telemedicine option. That service went live on galleri.com a few weeks back, and we believe it will become a significant growth driver ahead of reimbursement. Separately, we joined forces with PWNHealth, a national telehealth network, to broaden our service capability for certain employer programs. On top of that, in September, New York State gave the green light to the Galleri test. The bar set by New York State is among the toughest validation standards demanded of laboratory-developed tests. Last, there's enormous enthusiasm surrounding the recent launch of the NHS Galleri study — a 140,000-participant, real-world randomized controlled trial that has drawn extensive media attention both nationally and internationally. It forms part of England's national priority to accelerate earlier cancer detection and thereby improve survival. Enrollment has been strong and remains in line with what we expected. Drawing on data from this initial study, access to Galleri could reach roughly 1 million people across 2024 and 2025, and then a broader population beyond that point. To wrap up, I want to point out that the GRAIL revenue we reported comes from two sources: money we recognized from selling our Galleri tests, plus income produced by our MRD collaboration agreements with biopharma companies. The early test data we've gotten alongside our partners has been encouraging, and we intend to broaden several pilot studies to help advance development of MRD and PDX product opportunities. Beyond that, we anticipate that MRD and PDX collaboration income will remain a significant piece of GRAIL's revenue mix and serve as an appealing driver of future growth for our business. I'm eager to tell you more about how GRAIL is progressing in the quarters ahead; with that, I'll hand things over to Sam.
Sam Samad
executiveThanks, Bob. Just a note that our Q3 financials reflect GRAIL's consolidated results only from the point the deal closed, which was August 18, 2021. I'll go through our consolidated results first, then cover the segments for Core Illumina and GRAIL, and wrap up with the outlook. My focus will be on non-GAAP results, which factor in stock-based compensation. Please take a look at the GAAP reconciliation for these non-GAAP measures — it's in today's release and in the supplementary data on our website. Q3 revenue beat our expectations by a wide margin once again, up 40% year-over-year to $1.108 billion, with Core Illumina revenue rising 39% and $2 million coming from GRAIL. GAAP net income for the third quarter came to $317 million, or $2.08 per diluted share, and that figure includes a $900 million gain on our previously held GRAIL investment tied to the acquisition, plus $654 million in day one compensation expense connected to the GRAIL deal. Non-GAAP net income for Q3 was $221 million, or $1.45 per diluted share, which reflects $0.19 of dilution from GRAIL operating losses and $0.06 of incremental dilution from the 9.8 million shares we issued to fund the GRAIL acquisition. Our weighted average diluted share count for the quarter came in at roughly 153 million. Now for the remainder of the consolidated P&L. Non-GAAP operating expenses reached $528 million, up $57 million sequentially, mostly because GRAIL contributed $50 million in non-GAAP operating expenses for the quarter, along with a $7 million rise in core Illumina non-GAAP operating expenses. On a year-over-year basis, non-GAAP operating expenses rose $163 million, driven by $50 million of GRAIL non-GAAP operating expenses and a $113 million increase in core Illumina non-GAAP operating expenses. Non-GAAP other expense was $6 million, up $4 million sequentially and $13 million below the other income we saw in Q3 of last year, in line with expectations. That year-over-year decline stems mainly from lower interest income on short-term investments after we repositioned our investment portfolio and then liquidated those holdings to fund the GRAIL acquisition, plus interest expense on the term notes issued in Q1 2021. The non-GAAP tax rate came in at 13.2%, down from both last quarter and a year ago, reflecting the tax impact of bringing GRAIL into Illumina's consolidated results of operations. The year-over-year drop in the non-GAAP tax rate was partly offset by discrete tax benefits recorded in the third quarter of 2020 tied to prior year return adjustments and tax reserve releases. Turning to segment results, I'll begin with Core Illumina's financials. Core Illumina revenue climbed 39% year over year to $1.106 billion, powered by record shipments in both clinical and research. Core Illumina sequencing revenue was $1.013 billion, up 43% year-over-year and accounting for 92% of Core Illumina revenue. Core Illumina sequencing consumables revenue rose 45% year-over-year to $723 million, led by record NovaSeq consumable shipments that were up over 50% year-over-year. Core Illumina's sequencing instruments business rose 65% from a year earlier, reaching $180 million, helped by NovaSeq shipments hitting a record and once again doubling versus the prior-year period amid faster-growing demand for oncology testing. Orders for the NextSeq 1000 and NextSeq 2000 set a fresh quarterly peak, and every mid-throughput and low-throughput system posted healthy year-over-year gains. We closed out the quarter with a record backlog for sequencing instruments, nearly twice what it was when the year began. COVID-19 surveillance revenue beat our forecasts once more, reflecting continued emphasis on variant tracking and the buildout of surveillance infrastructure during the quarter, adding roughly $40 million of sequencing consumables revenue plus $15 million of incremental instrument revenue. Core Illumina sequencing service and other revenue climbed 11% over the prior year to $110 million, lifted by greater instrument service contract revenue from a larger installed base along with gel sample growth. Now for Core Illumina's regional results. The Americas region brought in $581 million, up 33% from the same period last year. Growth there came from record oncology testing shipments and ongoing population genomics programs like All of Us. Also fueling the region's performance was COVID surveillance strength, as public health networks in Latin America broadened their adoption of NGS. EMEA posted $313 million in revenue, a 47% year-over-year increase. EMEA's results reflected substantial growth across every clinical market and momentum in emerging markets. Population genomics efforts—partly tied to UK Biobank, which wrapped up in Q3—along with COVID surveillance testing contributed to the region's robust third quarter. Greater China revenue totaled $122 million, up 47% year-over-year, on continued clinical momentum there, led by NextSeq Dx demand from hospitals and growth in oncology testing. Nearly half of NextSeq Dx shipments went to hospital customers new to Illumina, and that widening hospital footprint is fueling growth in infectious disease testing, which more than doubled from a year ago. Lastly, APJ revenue of $90 million rose 45% year-over-year, driven by sequencing instrument growth from clinical demand for the NextSeq 2000 and by consumables revenue growth across oncology testing and research. Turning to the remainder of the Core Illumina P&L. Core Illumina non-GAAP gross margin came in at 71.3%, down 50 basis points from the previous quarter, mainly because of one-time revenue from the NIPT patent litigation settlement booked in the earlier quarter. Versus a year ago, non-GAAP gross margin was up 390 basis points thanks to greater fixed cost leverage on higher volumes, partly offset by elevated freight costs stemming from the pandemic. Core Illumina non-GAAP operating expenses were $478 million, $7 million above the prior quarter, yet overall came in below expectations because hiring and project spending shifted into Q4. As anticipated, non-GAAP operating expenses rose $113 million year over year, reflecting higher performance-based compensation expenses and headcount growth, plus additional investments supporting our business's significant growth. For Core Illumina, non-GAAP operating margin came in at 28%, versus 30% during the second quarter of 2021. As anticipated, operating margins fell on a sequential basis, largely because the earlier quarter included $20 million in one-time revenue from a patent litigation settlement. Now turning to how GRAIL performed financially. GRAIL's revenue for the quarter reached $2 million, made up mostly of fees for the Galleri test — the multi-cancer early detection test that became commercially available in June — along with a modest amount of MRD partnership revenue. GRAIL's non-GAAP operating expenses came to $50 million for the quarter, driven mainly by costs tied to headcount and clinical trials. Keep in mind that GRAIL's third quarter financial results cover only the period starting once the acquisition closed on August 18. Shifting to cash flow and balance sheet matters for consolidated Illumina. Cash flow used in operations amounted to $272 million, a net outflow for the quarter stemming from expenses connected to the GRAIL acquisition. DSO stood at 50 days, up from 44 days in the prior quarter, due to revenue linearity. Capital expenditures for the third quarter of 2021 totaled $52 million, while free cash flow was negative $324 million. No common stock was repurchased by us during the third quarter. We closed the quarter holding roughly $1.3 billion in cash equivalents and short-term investments.
Sam Samad
executiveIn Q3, $2.9 billion went toward funding the GRAIL acquisition. Ahead of talking about guidance, I want to say that I take particular pride in how well our team executed to meet surging demand and produce yet another record quarter amid a difficult global backdrop. There were a few limited areas where supply was tight for some products in certain geographies during the quarter, but because of our team's tremendous work, the impact was not material. We'll keep sourcing, producing, and operating nimbly so we can drive additional growth and serve our customers. Turning to 2021 guidance. We now anticipate that full year 2021 consolidated and core Illumina revenue will rise roughly 36%. That works out to consolidated revenue of about $4.41 billion for 2021, or roughly $1.17 billion of revenue growth versus 2020, and an increase of about $100 million relative to the midpoint of our earlier guidance. For fiscal 2021, we now anticipate core Illumina sequencing revenue rising about 39% year-over-year, fueled by ongoing momentum in our base business. We now anticipate core Illumina non-GAAP operating margin landing between 27.5%-28%, reflecting our higher revenue expectations. For Q4 2021, we anticipate core Illumina operating expenses rising by roughly $50 million versus Q3 2021, owing to the timing of expenses moving from Q3 into Q4, greater investments to support the robust growth of our business, along with expected payments in Q4 2021 tied to certain partnerships. Our focus remains on enhancing the core Illumina operating margin leverage over time. We now anticipate our non-GAAP tax rate of about 17.5%. We now anticipate consolidated non-GAAP earnings per diluted share between $5.50-$5.60, which includes dilution of approximately $1 from the GRAIL operating loss and incremental dilution of $0.15 from the 9.8 million shares issued to fund the GRAIL acquisition. We now anticipate GAAP earnings per diluted share between $4.41-$4.51. We now anticipate diluted shares outstanding in fiscal 2021 of roughly 151 million; for the fourth quarter of 2021, we anticipate non-GAAP earnings per diluted share between $0.35-$0.45, and GAAP earnings per diluted share between $0.10-$0.20. We anticipate diluted shares outstanding for the fourth quarter of 2021 of roughly 158 million. Now I'll turn the call back to Francis for his closing remarks.
Francis deSouza
executiveI appreciate that, Sam. The results we delivered in Q3 speak to how solid our business is, to the skill and commitment our employees bring, and to the lasting worth of the mission we serve. Before wrapping up, I want to call attention to the ways we are carrying that mission forward via our ESG efforts. The wellbeing of people and the wellbeing of the planet are connected, just as our corporate mission is connected to our pledge to run the business in a responsible and sustainable manner. During Q3, we rolled out ambitious environmental targets, among them a net zero pledge that moves the climate piece of our ESG approach ahead. Sam and I will go into more depth on that approach at our first-ever ESG investor event on November 16th, and we would love for you to be there. In closing, Q3 brought outstanding results and strength that was broad-based throughout our business, and we feel both inspired and excited to watch that momentum carry over into Q4. Once again we lifted our guidance for annual revenue and, thanks to a record instrument backlog, we are positioned for a powerful ending to a remarkable 2021. We will keep building on that strength as we take hold of chances to grow existing markets, such as oncology testing and infectious disease, plus new applications. Sequencing data will make that expansion possible as we bring in the period of genomic medicine. Illumina will lead the way on these innovations, standing behind our customers as together we move human health forward; at this point, I'll ask the operator to begin the Q&A.
Dan Brennan
analystGreat. For my first question, I'd like to dig into what the fourth quarter outlook looks like. After such a strong beginning to the year, you're raising guidance, yet the fourth quarter strikes us as conservative; so I'm curious about a few things. Does that outlook bake in anything further for COVID testing? I recall your original guidance had $25-$30 million per quarter; so have you revised that given how strong the COVID year was in Q3? And with the easy comp, plus the backlog and momentum, I'm wondering why the fourth quarter outlook wouldn't be stronger. Then I have a follow-up. Thank you.
Sam Samad
executiveThank you, Dan. This is Sam, and I hope you're doing well. Welcome back, and it's good to have you on the call. Regarding Q4, first let me address the full year. As we mentioned during the prepared remarks, Dan, we're raising our revenue guide to approximately 36%. For Q4, there are a couple of areas I think you should keep in mind. One is the UK Biobank initiative wrapping up. From a population genomic standpoint, this has been an incredibly productive, and I would say very important, initiative, and we discussed some of the outcomes from it along with the next steps. But in Q4 versus Q3, that will likely create a $20 million quarter-to-quarter headwind, or reduction, when it comes to revenues. That's one area. Then the second area — and I think you touched on it in your question — concerns COVID surveillance. COVID surveillance has been strong throughout the year; we've obviously seen, with the pandemic the way it is, continued testing and sequencing of positive samples across the globe. In Q3, we had $55 million of COVID surveillance revenue for the quarter. That broke down as $15 million of instruments and $40 million of consumables. For Q4, we expect $35 million of COVID surveillance revenue, which breaks down as a modest amount of instrument revenues, about $5 million, and then approximately $30 million of COVID consumables; that's again another $20 million reduction from Q3 into Q4. When we think about that sequential momentum, the core business is really strong. By the core business, I mean our clinical business and research business. You heard comments from Bob around GRAIL, but there is that reduction tied to those two items, which is COVID surveillance as well as the UK Biobank concluding.
Dan Brennan
analystFantastic. On the clinical side, Francis, regarding therapy selection, you provided quite a bit of detail and mentioned that customers are quickly adding platforms. Could you help us understand—I'm not sure whether you have this data—the installed base backing this customer group, what rate it's been increasing at, and also what the backlog looks like along with the outlook for additional growth in that space? Thanks.
Francis deSouza
executiveYes. Thank you, Dan, and glad to have you at Cowen—it's wonderful to see you following us once more. I discussed at length the momentum in the oncology segment, particularly oncology therapy selection testing, since that truly has been among the standout narratives, honestly, throughout the entire year. A handful of factors are really propelling that narrative. First, a major broadening in reimbursement for genomic testing for therapy selection occurred across the U.S.; at this point we possess a substantial base within the U.S. covered for genomic testing. Simultaneously, we've observed a shift toward bigger panels as comprehensive genomic profiling gains real momentum in the marketplace. Together those have generated a potent dynamic in oncology therapy selection testing, and we're watching our customers enlarge their instrument fleets. Regarding how this is unfolding, we're seeing it happen in every segment. Some of our bigger customers are considerably growing their fleets and specifically growing their NovaSeq fleet, driven by the demand they're encountering plus the demand they expect ahead. You're additionally seeing new customers and certain smaller customers enter oncology therapy selection. A notable metric worth examining—and it reflects more than oncology, though I'd argue oncology ranks among its largest drivers—is that when you examine the momentum in NovaSeq instruments, you'd notice we're putting many NovaSeq instruments in place, and we're carrying a very robust backlog of NovaSeq instruments. Meanwhile, you're witnessing genuinely powerful pull-through on NovaSeq. That's essentially, you know, the treasure waiting at the finish of the double rainbow, correct? Because you're observing that we're deploying plenty of instruments, and still pull-through stays elevated at the top end of the range we've discussed. As for your question regarding, you know, the outlook ahead, I'd call that a genuinely encouraging signal for what people are going through today and what they anticipate ahead.
Dan Brennan
analystExcellent. Thank you, Francis.
Vijay Kumar
analystHello everyone, nice work on the strong results, and I appreciate you fielding my question. I've got just one thing regarding what fiscal 2022's guidance suggests for Q4. With the revised EPS outlook at $5.50-$5.60, that works out to roughly $0.30-$0.40 for Q4, if I'm calculating correctly. Is that right for Q4? Are there any non-recurring charges, or is something unusual going on, since that annualizes to $1.60? That doesn't seem correct to me. I simply want to confirm my Q4 assumptions are accurate; when it comes to fiscal 2022, should comps matter, since many of your competitors are, as you know, expecting normalized growth, and could you comment on backlog? I realize surveillance is a major piece for you this year, but regarding that 36%, should comps matter, and what's the right way to think about that?
Sam Samad
executiveYes. I'll begin with Q4, Vijay. We mentioned, as you know, an EPS guide of $0.35-$0.45, non-GAAP EPS for Q4, as you know, factoring in GRAIL's effects. As I said during the call, in Q4, as you know, dilution is roughly $0.80, $1 for the entire year, but during Q4, approximately $0.80 tied to GRAIL dilution. On top of that, there's roughly $0.09 of dilution tied to the weighted average share count, coming from shares we issued to fund the GRAIL acquisition; those relate specifically to GRAIL; that clearly affects the $0.35-$0.45 non-GAAP EPS for Q4; when it comes to the core Illumina business, as you know, I responded to Dan's question, I discussed somewhat a few dynamics regarding revenue. On the OpEx side, certain costs exist that I also referenced during our prepared remarks. To begin with, we have expense timing that moved from Q3 into Q4. That's the reason Q3 came in below our expectations regarding operating expenses. Q4 has now risen in terms of what we expect to spend there. I also discussed partnership OpEx anticipated during Q4. We have certain expenses tied to particular partnerships that are somewhat substantial in Q4 and are discrete to Q4. As you know, regarding 2022 guidance, we won't discuss guidance during this call, other than to say the business fundamentals are extremely strong; we've previously discussed the GRAIL dilution of $3.25-$3.75 for 2022. That's still true. Nothing there has changed. As you heard, backlog is extremely strong when it comes to instruments, and the core fundamentals regarding clinical and research are extraordinarily strong.
Vijay Kumar
analystJust to be clear on one thing, Sam. Regarding that $3.25 to $3.75 dilution tied to GRAIL — that isn't additional, correct? During fiscal 2021, you already absorbed $1.15 of dilution. So the $3.25 to $3.75 figure includes that $1.15.
Sam Samad
executiveFor GRAIL in 2022, that represents the entire dilution; it isn't incremental. That's the full amount of dilution we anticipate. An impact of $3.25 to $3.75 on non-GAAP EPS.
Vijay Kumar
analystAppreciate the clarification. So that was in 2022. Understood. Thank you. Thanks, everyone.
Francis deSouza
executiveYou're welcome.
Tycho Peterson
analystHi, thanks. Sam, I'd like to dig a bit deeper into what you said about the supply chain. From what I can tell, disruption has been fairly minimal so far. We've been hearing that customers can't obtain flow cells and get short notice on deliveries, and you finished the quarter with record backlogs. Could you speak to how the supply chain looks right now, given the widely flagged and heavily covered shortages of semis, plus cameras and high-end opticals?
Francis deSouza
executiveYes. Hi, Tycho, Francis here. Let me begin by noting that's a fair question, since whenever you post a beat this large and see demand arriving well beyond what was expected — I believe the guidance we've now issued sits more than $500 million above the midpoint of the guidance we gave at the start of the year — whenever a beat that size unfolds while a pandemic is ongoing, the first area you examine is the supply chain and whether you can serve your customers. Like we mentioned on the call, I feel enormous pride in what the team has accomplished on demand capacity planning, ensuring we can keep pace with this substantial demand we're experiencing. As we noted, this demand began building late last year. The teams put in extensive effort on several fronts. First, they worked to guarantee our inbound suppliers could handle the incoming demand; that involved steps such as holding safety stock of incoming supplies internally, placing orders for long-lead-time items — occasionally a year or more ahead for items like resins, where we anticipated possible shortages. Beyond that, we began investing to raise our own production capacity, and that applied everywhere. Be it reagents, cartridges and flow cells, or arrays, in every area we began substantially boosting capacity to manufacture supplies, certainly by the first half of this year. On top of that, beginning last year we started investing to grow our capacity for relocating production. As one example, we enlarged our warehousing footprint in Eindhoven and launched a new facility there — that's our regional distribution hub for EMEA, in case you didn't know — and we doubled what we had in Eindhoven. In the same way, we grew our warehousing capacity in Japan this year. We added a new warehouse in Brazil this year. We also kept investing to reinforce the transportation connections among these hubs. After that, we began establishing safety stock over on the outbound side, so we'd be certain there was sufficient inventory at our sites to handle what we already understood would be robust demand — and it turned out to be far more robust than even our own projections had suggested; at this point, for the great bulk of our core consumables, you know, we're holding safety stock that equals 6 to 8 weeks of supply. Our team truly did a fantastic job, in a sense, identifying this early and then attacking it from beginning to end, ensuring we possessed the capacity needed to meet the incoming demand.
Sam Samad
executiveYes. The one point I'd tack on there — thanks, Francis — is that demand is truly what's fueling our very robust backlog. Everything Francis brought up reflects steps we've implemented so that our supply chain keeps running smoothly and so that customer orders get delivered on schedule. I'd characterize it as a handful of scattered customer situations involving longer lead times, which isn't unusual. We encounter that kind of thing each quarter; by and large, what's behind the backlog is demand, not any kind of supply problem creating it.
Tejas Savant
analystHi everyone, good evening. I've got one brief item regarding GRAIL. Francis, is there anything new on the regulatory side, given that they've now had a bit of time to absorb the choice you made to close? Has any feedback come your way about how that separate agreement is structured, or about whether a fine might come? And second, could you share how you intend to expand the commercial build-out, now that Galleri has launched and you're beginning to see early momentum from the Mayo Clinic plus a few of the other partners you mentioned during prepared remarks?
Francis deSouza
executiveTejas, perhaps I'll address the regulatory side first, then hand things to Bob for his thinking on commercial growth. Looking at the regulatory side, nothing unexpected has come up. Honestly, it's unfolding exactly the way we anticipated. We're involved in two proceedings with the European Commission, and those are moving along; we hope to receive a ruling on the phase II review taking place in Europe near the close of Q1, though it could shift somewhat. We're awaiting the trial date for the jurisdiction trial being held in Brussels. It's going the way we expected. Here in the US, we're still finishing up the administrative trial I described earlier, and we anticipate a ruling, probably in Q1. Could be near the end of the year, but Q1 seems more likely. Things are unfolding as anticipated when it comes to the hold separate. The order was issued, and it matched what we'd assumed it would be, and broadly matched the hold separate we ourselves chose to implement voluntarily, expecting this outcome; overall, nothing truly unexpected. The process is moving forward as we intended. I'll now pass it to you, Bob.
Bob Ragusa
executiveHello, and thank you, Francis, for bringing up the commercial build-out. As we examine the demand landscape, we're seeing substantial pre-reimbursement possibilities for Galleri, spanning three primary avenues: employers, health systems, and medical practices. A crucial part of collaborating with the team right now involves ensuring we can genuinely increase the commercial scale of the organization to satisfy the demand that exists. Beyond that, it's not only about the commercial aspect. We'll need to scale up essentially the whole operation so that we're able to provide an excellent customer experience at scale. That will require us to build across numerous functions throughout the company. I'm truly thrilled to tackle that challenge, since we're fortunate enough to have such a powerful product, and now we're really building out — we have the chance to build out every commercial component and every delivery component so that we can deploy Galleri on a large scale.
Francis deSouza
executiveOkay, let me tack on one more item, and this one comes from my own experience. We made the Galleri test available to folks working at Illumina, and I realize a number of you on this call might have gone through the same thing. As a chief executive, honestly, only a handful of moments in your whole career let you launch something that everybody genuinely likes and that also ends up costing you less. We began hearing from some of the earliest participants who got in touch and told us they consider themselves lucky, since the Galleri test allowed them to catch a cancer at an early stage — and the cancers in question happen to be types lacking any other screening option. For me, that's a deeply personal way of understanding just how much this test can do.
Patrick Donnelly
analystHi, everyone. Appreciate you answering our questions. Francis, perhaps a question regarding China. Could you share what you're observing in that market? Clearly, there's considerable chatter across various segments. Your company delivered fairly solid results. Could you discuss the patterns you're noticing there as well as what you anticipate ahead?
Francis deSouza
executiveChina has kept delivering exceptionally robust results for us, with growth of 47% compared to the prior year across the board. Growth there, you know, is still being powered by the clinical markets, and the approach we kicked off last year—zeroing in on the emerging hospital market—is genuinely bearing fruit. That market is enthusiastically adopting not only NIPT, which it took up early on, but also, more and more, beginning to expand oncology testing and genomic testing on a wider basis. We're making headway in that area. A great deal of this stems from the fantastic partner ecosystem we've established in China over the years, and that is truly delivering returns. On top of that, we're genuinely experiencing a favorable push tied to certain regulations that have come about permitting LDT use in Shanghai. You know, that development is relatively new, yet it has already begun yielding benefits, as you can observe more labs being established to build out their own LDT testing capacity. That has, you know, worked in our favor and is generating part of that favorable push. Right now, we are unquestionably thrilled and hopeful regarding what is taking place in China for us.
Patrick Donnelly
analystAlright. Perhaps a question regarding population sequencing. As you mentioned, this quarter marked the completion of UK Biobank. Could you give us an update on your confidence as those get deployed and, once more, as we observe some information and witness how UK Biobank is being utilized, the possibility for that to grow into a larger component for you folks?
Francis deSouza
executiveYes, definitely. One really encouraging development has been how much wider the group of population sequencing customers has become. We've mentioned before that we've been developing more than 50 of these opportunities, and at this point over 30 of them are already bringing in revenue. From a diversification standpoint, that's genuinely good to see. Another great aspect is that many of these population sequencing initiatives are being pushed forward from a national health standpoint. These aren't research projects. What you're witnessing is nations adopting genomic testing as part of standard care within a health system. That's wonderful, first of all, because of the deeply human impact it lets you have, since you're involved in the process of delivering valuable information to patients; it's also an area that's highly durable, correct? It means once you're embedded in the healthcare system, you simply get scaled up to population level, and it continues year after year. That's yet another truly exciting thing to witness. Something else that's unfolding is that we're beginning to see cohorts emerge, many of them with pharma partners that want to produce data from population-level data drawn from some of the large data repositories around the globe, such as biobanks. That's currently an emerging and growing piece of the population sequencing ecosystem as well.
Michael Ryskin
analystHello, this is Mike Ryskin, stepping in for Derik. Thanks for letting me ask something. I have a few quick questions, and I'll focus only on the sequencing instruments side of things. You described strength as really broad-based, naming NovaSeq, NextSeq 1000 to 2000, and MiSeq, if I recall correctly. That accounts for the majority of what you offer. Even so, sequencing instrument revenue overall declined from one quarter to the next. I'd like to know if you can speak to pricing trends or ASPs—did anything out of the ordinary occur around the middle of the year? I have one more question after that.
Sam Samad
executiveYes, thank you. Thanks, Mike, and I appreciate the question. Honestly, when you look at instrument demand, nothing meaningful really shifted as we moved from Q2 to Q3. Sure, instrument revenue does tend to fluctuate a bit from one quarter to the next. NovaSeq posted its best-ever quarterly revenue, and placements hit a record too — we doubled what we did a year ago. Like we mentioned, we closed out the quarter sitting on a record instrument backlog. There may be a few tiny shifts in one place or another, but nothing stands out as the reason Q3 came in a little lower than Q2. Regarding COVID monitoring, another thing that played a small role moving from Q2 to Q3 was our sequencing instrument placements. We put out slightly fewer sequencers during Q3 than we had in Q2, so that also created a modest effect. That said, as we've talked about, overall demand has been remarkably robust—our NextSeq 2000, 1000, and 550 installations have doubled relative to earlier years, and I don't just mean last year but going further back historically, compared with what we typically placed in the mid-throughput segment—and on top of that, NovaSeq demand has been extraordinarily powerful. To echo what Sam mentioned, as we head into Q4, we're sitting on an all-time high instrument backlog, which is a great position to be in. NovaSeq set a record for instrument shipments during Q3. When it comes to NovaSeq pull-through, despite all the units we've just installed—many of which you'd expect are still ramping up and therefore should be showing pull-through at the lower end—the overall average pull-through for NovaSeq remains at the upper end of the range we've previously discussed. That's holding steady. NovaSeq units are seeing heavy use in customer labs right now, which is prompting buyers to submit orders — and those orders are what's building the record backlog we're carrying into Q4. Honestly, we consider that an incredibly powerful spot to find ourselves in.
Puneet Souda
analystThank you, Francis, and I appreciate you fielding this. To begin, regarding GRAIL — and this may be partly for Francis and partly for Bob — when it comes to the studies you must run right now, you brought up the U.K. NHS study that's underway. Clearly, you've made a commitment to GRAIL and absorbed the dilution. As for the full set of trials required — prospective registrational studies the FDA must review, studies that reflect prevalence — so that a screening assay can secure market approval, could you just take us through that? What steps are you taking to move forward on it? What's the timeline? Which trial is it? Does the U.K. NHS study count as that trial, or is there some other study, or biobank samples you've already gathered that you could potentially analyze and submit data from? I'm just trying to get a handle on that trial of over 50,000 or 100,000 patients that's required to obtain FDA approval and, after that, reimbursement and inclusion in guidelines.
Francis deSouza
executiveSure, I'll begin and then hand it to Bob. What I'd say is this: what we've stated previously remains accurate as of today, meaning that here in the U.S., the test has been launched as an LDT, and nothing further is required. It's available on the market right now. It's a self-pay test. You can place an order today. Certain employers already provide coverage for it. A number of health systems are considering deploying it within the concierge system; that might take the form of a subscription model, for instance, or other structures. In the U.S., nothing is required for the test to stay on the market, and it has been available since June. Regarding trials, nothing is required for the current revenue streams Bob described to become reality. As for studies and data, all of it is already available. In fact, the early read studies we'll likely present to you this year merely confirmed once more the enormous quantity of data already released to the market. Nothing further is required on that front. What we've said regarding the NHS is that the NHS functions as a self-contained trial in the sense that it has established the milestones and the progress that would make it comfortable expanding to population scale. They were the ones who laid out the path stating it could begin at 140,000, then grow to 1 million over the next couple of years, and afterward move to population scale. It's an entirely self-contained process. They've determined what they need to observe. They're working in partnership with GRAIL. That's what we've said previously, and that's what we continue to see. I'll hand it over to Bob.
Bob Ragusa
executiveAppreciate that, Francis. Yeah, perhaps a handful of additional points worth making. There are really 3 main pieces here pushing us toward that goal. First is the NHS trial we've discussed, which involves 140,000 people and will keep growing in scope as the years go by. That's going to give us a massive collection of data. Then there's PATHFINDER, wrapping up midway through next year. Up to this point, what we've seen from that has largely lined up with the earlier validation findings. So it's been quite encouraging so far. Beyond that, there's the Galleri REFLECTION registry trial, where we'll examine how things go clinically and in terms of patient experience for 35,000 screening-eligible individuals aged over 50 who got the test through a healthcare provider's order. Enrollment on that kicked off during this quarter, and it too will yield substantial data as we move along the path toward reimbursement. I'd also like to build on something Francis mentioned: regardless of reimbursement being in place, there's a huge amount of activity and opportunity for Galleri that comes before reimbursement. Sure, getting to reimbursement matters enormously, but that isn't the sole thing to consider.
Kyle Mikson
analystHi there, and thanks for fielding the questions. I'd like to combine a couple of items here regarding GRAIL. To begin with timelines — I realize this came up before, but the EU investigation that had been paused has now restarted. A decision should arrive in early February at this point. And frankly, for the trials and reviews, most outcomes are anticipated during the first quarter of 2022. I simply wanted to ask how much visibility will be offered once those events wrap up? Clearly, this has been a fairly divisive subject. I figure it would help to grasp how much insight we can expect concerning, I suppose, the regulatory result beyond the first quarter of 2022. One more item to add here. GRAIL's revenue — its performance this quarter — appears to have been roughly $5 million. If we distribute that across the three months, it annualizes to $20 million. I'd just like to grasp what the test volume trends might be, and perhaps reimbursement too. That would be useful. Thanks.
Francis deSouza
executiveYes. Perhaps I'll begin by saying, look, when we consider GRAIL and, in a sense, the road ahead regarding visibility, I realize investors have raised this question. From our standpoint, clearly we will keep working through the trial process, and I'll update you on that. What we aim to do is ensure that, you know, GRAIL keeps generating value. The reason is that regardless of which scenario unfolds, you know, should we complete things and hold GRAIL and be able to expand it, that's an enormous success obviously and extremely valuable for our shareholders. We recognize that if we generate a great deal of value in GRAIL, then whatever the regulatory result turns out to be, it remains a major win, not just for individuals being screened, but for our shareholders as well, since we'll possess an asset that has appreciated considerably. Even considering the progress achieved at GRAIL since the deal was announced, correct? Since we announced the deal, they've, you know, published some of their study results; they launched a product according to the schedule they set in June. They have, you know, not merely signed the NHS deal, but begun the rollout to 140,000 customers and enrolled some additional healthcare systems and employers in the U.S. It's evident the business has generated substantial value compared with maybe 12, 15 months ago when we announced the deal. Part of our focus will also simply be ensuring that Bob and his team possess everything required to go build a hugely valuable business. That accomplishes this: it guarantees our shareholders, in a sense, that whatever the outcome may be, it's a win for our shareholders. I just want everyone to be really clear that this keeps going on even as we're having this conversation, and it's happening alongside the trial. When it comes to the trial, we're expecting rulings out of Europe on two different fronts, correct? Like you mentioned, for the phase II data, the current date is February 24th. There could be a slight delay, but we anticipate those phase II findings around then. Late in Q1, possibly early in Q2. We're also waiting on a date at the tribunal in Brussels regarding jurisdiction, and that too falls in the first half, perhaps Q1, perhaps Q2. If we win on either of those, our regulatory work in the European Union is finished. If we lose, then based on which one it is, there are particular appeal paths you follow. Over at the FTC, we're still expecting a ruling, as I mentioned, during Q1 in connection with the administrative process. After that, there will unavoidably be a re-review or an appeal before the commissioners; then, if we don't win at any of those stages, we head to district court, likely in the latter part of next year. So that's how the process works. I'll hand things over to Bob in case he has anything else to add.
Bob Ragusa
executiveRegarding the revenue question, yes. So GRAIL's top line includes money we book from selling the Galleri test plus income produced by our MRD partnership deals with biopharma firms. We anticipate that the MRD PDX collaboration income will remain a significant part of GRAIL's revenue and an appealing future growth driver for our business. During the early launch phase, we do anticipate that the mix of the GRAIL pharma MRD revenue components will vary from one quarter to the next. The total revenue figure isn't truly a strong signal of sample volume, given the pricing mix and all that.
Brian Blanchett
executiveAppreciate it. Just a quick note that a recording of today's session can be accessed under the investor portion of our site, and you can also find dial-in details in the earnings release we put out today. We're glad you could be with us. That wraps up this call, and we're eager to speak with you again on our next update call when 2021 comes to a close.
Operator
operatorThanks once more for being with us on this Illumina Q3 2021 earnings call. That brings today's call to a close. You're free to hang up your lines now, and we hope you have a lovely day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.